Alumis
Martin Babler is a seasoned executive with extensive experience in the biopharmaceutical industry. Currently serving as Chairman, President, and CEO of Alumis since September 2021, Babler also holds multiple board positions, including Board Member at Prelude Therapeutics, Sardona Therapeutics, Omega Alpha SPAC, and Neoleukin Therapeutics. Previously, Babler was the President and CEO of Principia Biopharma from April 2011 to October 2020 and led Talima Therapeutics in the same executive role from December 2007 to April 2011. Additional experience includes co-ownership of Paradigm Ranch Management LLC since February 2008 and a board member role at ZS Pharma, Inc. and MMA. Babler's leadership roles reflect a strong commitment to advancing therapeutic innovations and strategic growth in the biopharmaceutical sector.
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.